Targeting the MLL complex in castration-resistant prostate cancer
收藏官方服务：
资源简介：
Targeting the MLL complex in castration-resistant prostate cancer
应用场景：
创建时间：
2015-02-27
相关数据集
Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (microarray)
Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly
NIAID Data Ecosystem70
The novel p300/CBP inhibitor A-485 uncovers a unique mechanism of action to target AR in castrate resistant prostate cancer
The novel p300/CBP inhibitor A-485 uncovers a unique mechanism of action to target AR in castrate resistant prostate cancer Descriptor: Histone acetyltransferase p300, N-[(4-fluorophenyl)methyl]-2-{(1
Protein Data Bank Japan2023-09-27 更新40
LSD1 inhibition disrupts super-enhancer activities in CRPC [RNA-seq]
Our studies revealed a novel oncogenic function of LSD1 in driving PCa progression by activating MYC signaling and mediating CRPC SEs activities, cotargeting LSD1 and BRD4 achieved significant synergi
NIAID Data Ecosystem10
Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation
The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus. However, some patient
Figshare2016-01-18 更新40
Gene Expression Analysis of metastatic CRPC cell line C4-2B treated with the dual BET-kinase inhibitor MA4-022-1
We identified BRD4 as an epigenetic regulator of the prostate lineage specific gene HOXB13 during progression of the disease from an androgen dependent to an androgen independent state. Overall desi
NIAID Data Ecosystem10
